AR056396A1 - Composicion inmunogenica - Google Patents
Composicion inmunogenicaInfo
- Publication number
- AR056396A1 AR056396A1 ARP060102723A ARP060102723A AR056396A1 AR 056396 A1 AR056396 A1 AR 056396A1 AR P060102723 A ARP060102723 A AR P060102723A AR P060102723 A ARP060102723 A AR P060102723A AR 056396 A1 AR056396 A1 AR 056396A1
- Authority
- AR
- Argentina
- Prior art keywords
- immunogenic composition
- meningitidis
- polysaccharide
- capsular
- serogroups
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16271—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente solicitud describe una composicion inmunogénica que comprende polisacáridos capsulares de N. meningitidis de al menos una de los serogrupos A, C, W135 e Y conjugados con una proteína vehículo para producir un conjugado de polisacárido capsular de N. meningitidis, en el que el tamano medio de cada polisacárido de N. meningitidis es superior a 50 kDa.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0513071.1A GB0513071D0 (en) | 2005-06-27 | 2005-06-27 | Immunogenic composition |
GBGB0513069.5A GB0513069D0 (en) | 2005-06-27 | 2005-06-27 | Immunogenic composition |
GB0515556A GB0515556D0 (en) | 2005-07-28 | 2005-07-28 | Immunogenic composition |
GB0524204A GB0524204D0 (en) | 2005-11-28 | 2005-11-28 | Immunogenic composition |
GB0526040A GB0526040D0 (en) | 2005-12-21 | 2005-12-21 | Immunogenic composition |
GB0526041A GB0526041D0 (en) | 2005-12-21 | 2005-12-21 | Immunogenic composition |
Publications (1)
Publication Number | Publication Date |
---|---|
AR056396A1 true AR056396A1 (es) | 2007-10-10 |
Family
ID=36716943
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060102725A AR053935A1 (es) | 2005-06-27 | 2006-06-23 | Composicion inmunogenica |
ARP060102724A AR056397A1 (es) | 2005-06-27 | 2006-06-23 | Composicion inmunogenica |
ARP060102723A AR056396A1 (es) | 2005-06-27 | 2006-06-23 | Composicion inmunogenica |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060102725A AR053935A1 (es) | 2005-06-27 | 2006-06-23 | Composicion inmunogenica |
ARP060102724A AR056397A1 (es) | 2005-06-27 | 2006-06-23 | Composicion inmunogenica |
Country Status (37)
Country | Link |
---|---|
US (13) | US8431136B2 (es) |
EP (11) | EP1896061B1 (es) |
JP (9) | JP5731737B2 (es) |
KR (7) | KR101359953B1 (es) |
CN (3) | CN102218138A (es) |
AP (1) | AP2436A (es) |
AR (3) | AR053935A1 (es) |
AT (3) | ATE516816T1 (es) |
AU (7) | AU2006263964B2 (es) |
BE (1) | BE2012C042I2 (es) |
BR (5) | BRPI0612655B1 (es) |
CA (5) | CA2611960C (es) |
CY (5) | CY1109996T1 (es) |
DE (1) | DE602006013313D1 (es) |
DK (7) | DK2283857T3 (es) |
EA (4) | EA013374B1 (es) |
ES (9) | ES2747025T3 (es) |
FR (1) | FR22C1008I2 (es) |
HK (4) | HK1114011A1 (es) |
HR (4) | HRP20100211T1 (es) |
HU (7) | HUE046905T2 (es) |
IL (8) | IL187924A (es) |
LT (1) | LT2351578T (es) |
LU (1) | LU92085I2 (es) |
MA (4) | MA29602B1 (es) |
MX (5) | MX2007016402A (es) |
MY (3) | MY147490A (es) |
NL (1) | NL300549I2 (es) |
NO (4) | NO345422B1 (es) |
NZ (6) | NZ564370A (es) |
PE (6) | PE20070123A1 (es) |
PL (8) | PL1896062T3 (es) |
PT (8) | PT1896063E (es) |
SI (8) | SI1896065T2 (es) |
TW (5) | TWI537001B (es) |
UA (2) | UA95238C2 (es) |
WO (6) | WO2007000327A1 (es) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8189501A (en) * | 2000-06-29 | 2002-01-08 | Smithkline Beecham Biolog | Vaccine composition |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
JP4827726B2 (ja) | 2003-01-30 | 2011-11-30 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 複数の髄膜炎菌血清群に対する注射可能ワクチン |
GB0408977D0 (en) * | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
US8431136B2 (en) * | 2005-06-27 | 2013-04-30 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
AU2012261764B2 (en) * | 2005-09-01 | 2016-09-08 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | Multiple vaccination including serogroup C meningococcus |
RU2457858C2 (ru) | 2005-09-01 | 2012-08-10 | Новартис Вэксинес Энд Дайэгностикс Гмбх Унд Ко Кг | Множественная вакцинация, включающая менингококки серогруппы с |
JO2813B1 (en) | 2005-12-22 | 2014-09-15 | جلاكسو سميث كلاين بايولوجيكالز اس.ايه | A vaccine with multiple pneumococcal saccharides |
US10828361B2 (en) * | 2006-03-22 | 2020-11-10 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
ES2670231T3 (es) * | 2006-03-22 | 2018-05-29 | Glaxosmithkline Biologicals S.A. | Regímenes para inmunización con conjugados meningocócicos |
GB0612854D0 (en) | 2006-06-28 | 2006-08-09 | Novartis Ag | Saccharide analysis |
EP2066344B2 (en) | 2006-09-07 | 2016-06-29 | GlaxoSmithKline Biologicals S.A. | Inactivated Poliovirus combination vaccine |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
GB0700136D0 (en) | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Process for manufacturing vaccines |
GB0700135D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Vaccine |
PT2167121E (pt) | 2007-06-26 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vacina compreendendo conjugados de polissacáridos capsulares de streptococcus pneumoniae |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
US20160228500A9 (en) * | 2007-07-23 | 2016-08-11 | Martina Ochs | Immunogenic Polypeptides and Monoclonal Antibodies |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
ES2383231T3 (es) | 2007-10-19 | 2012-06-19 | Novartis Ag | Formulaciones para vacunas meningocócicas |
JP5769624B2 (ja) * | 2008-08-28 | 2015-08-26 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
AU2009309416B2 (en) | 2008-10-27 | 2015-05-28 | Glaxosmithkline Biologicals S.A. | Purification method |
GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
US20100189737A1 (en) | 2008-12-17 | 2010-07-29 | Arico Beatrice | Meningococcal vaccines including hemoglobin receptor |
BRPI1009829A2 (pt) | 2009-03-24 | 2016-11-16 | Novartis Ag | combinações de proteína de ligação de fator h meningocócico e conjugados de sacarídeos pneumocócicos |
CN104548082A (zh) | 2009-03-24 | 2015-04-29 | 诺华股份有限公司 | 为脑膜炎球菌因子h结合蛋白添加佐剂 |
JP5593626B2 (ja) * | 2009-03-31 | 2014-09-24 | 凸版印刷株式会社 | 計量スプーン |
SI2510947T1 (sl) | 2009-04-14 | 2016-05-31 | Glaxosmithkline Biologicals S.A. | Sestavki za imunizacijo proti Staphylococcus aureus |
EP2424562B1 (en) * | 2009-04-30 | 2015-10-07 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
GB0910046D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
AU2010301043B2 (en) * | 2009-06-22 | 2014-01-09 | Wyeth Llc | Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
MX2012000044A (es) | 2009-06-22 | 2012-01-30 | Wyeth Llc | Composiciones inmunogenicas de antigenos de staphylococcus aureus. |
MX2012002723A (es) | 2009-09-02 | 2012-04-11 | Novartis Ag | Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll. |
US20120237536A1 (en) | 2009-09-10 | 2012-09-20 | Novartis | Combination vaccines against respiratory tract diseases |
EP3199177A1 (en) * | 2009-10-30 | 2017-08-02 | GlaxoSmithKline Biologicals S.A. | Purification of staphylococcus aureus type 5 and type 8 capsular saccharides |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
ES2707778T3 (es) | 2009-12-30 | 2019-04-05 | Glaxosmithkline Biologicals Sa | Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli |
TW201136603A (en) * | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
GB201003924D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
CA2803239A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins |
WO2012025873A2 (en) | 2010-08-23 | 2012-03-01 | Wyeth Llc | STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS |
ES2458355T3 (es) | 2010-09-01 | 2014-05-05 | Novartis Ag | Adsorción de inmunopotenciadores sobre sales metálicas insolubles |
AU2011300418B2 (en) | 2010-09-10 | 2016-05-12 | Glaxosmithkline Biologicals Sa | Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom |
PE20140173A1 (es) | 2010-09-10 | 2014-02-20 | Wyeth Llc | Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis |
WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
RU2013144207A (ru) | 2011-03-02 | 2015-04-10 | Новартис Аг | Комбинированные вакцины с пониженными дозами антигена и/или адъюванта |
GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
CN104080479B (zh) | 2011-11-07 | 2019-11-05 | 葛兰素史密丝克莱恩生物有限公司 | 包括spr0096和spr2021抗原的运载体分子 |
JP2013112653A (ja) * | 2011-11-30 | 2013-06-10 | Jnc Corp | 新規重合体およびその製造方法 |
GB201121301D0 (en) | 2011-12-12 | 2012-01-25 | Novartis Ag | Method |
AU2011384634A1 (en) | 2011-12-29 | 2014-06-19 | Novartis Ag | Adjuvanted combinations of meningococcal factor H binding proteins |
CA2863178C (en) * | 2012-01-30 | 2021-04-06 | Serum Institute Of India Ltd. | Immunogenic composition |
EP2809785B1 (en) | 2012-02-02 | 2017-11-01 | GlaxoSmithKline Biologicals SA | Promoters for increased protein expression in meningococcus |
CN102569723A (zh) * | 2012-02-13 | 2012-07-11 | 华为技术有限公司 | 锂离子电池正极材料及其制备方法、正极及锂离子电池 |
WO2013131983A1 (en) | 2012-03-07 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of streptococcus pneumoniae antigens |
EP2822584A1 (en) | 2012-03-08 | 2015-01-14 | Novartis AG | Combination vaccines with tlr4 agonists |
RU2014140521A (ru) | 2012-03-08 | 2016-04-27 | Новартис Аг | Адъювантные составы бустерных вакцин |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
SG10201602558UA (en) | 2012-03-09 | 2016-05-30 | Pfizer | Neisseria meningitidis compositions and methods thereof |
KR102057217B1 (ko) * | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
CA2882619A1 (en) | 2012-09-06 | 2014-03-13 | Novartis Ag | Combination vaccines with serogroup b meningococcus and d/t/p |
ITMI20121597A1 (it) * | 2012-09-25 | 2014-03-26 | Beta Pharma S A | Coniugato tra frammento di parete cellulare batterica ed un veicolo mucopolisaccaridico e suoi usi in ambito medico |
WO2014053521A2 (en) | 2012-10-02 | 2014-04-10 | Novartis Ag | Nonlinear saccharide conjugates |
CN111249455A (zh) | 2012-11-30 | 2020-06-09 | 葛兰素史密丝克莱恩生物有限公司 | 假单胞菌抗原和抗原组合 |
KR20140075196A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
CN105007935A (zh) | 2012-12-18 | 2015-10-28 | 葛兰素史密丝克莱恩生物有限公司 | 用于保护免于白喉和/或破伤风的缀合物 |
TR201807340T4 (tr) | 2013-02-01 | 2018-06-21 | Glaxosmithkline Biologicals Sa | Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi. |
EP2964665B1 (en) | 2013-03-08 | 2018-08-01 | Pfizer Inc | Immunogenic fusion polypeptides |
HUE051592T2 (hu) * | 2013-03-18 | 2021-03-01 | Glaxosmithkline Biologicals Sa | Kezelési módszer |
CA2923129C (en) | 2013-09-08 | 2020-06-09 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
IN2014DE02450A (es) | 2013-09-25 | 2015-06-26 | Suzuki Motor Corp | |
RU2535122C1 (ru) * | 2013-11-06 | 2014-12-10 | Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") | Способ получения холерогена-анатоксина |
PE20212335A1 (es) * | 2014-01-21 | 2021-12-16 | Pfizer | Composiciones inmunogenicas que comprenden antigenos sacaridos capsulares conjugados y usos de los mismos |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
EP2921856B1 (en) | 2014-03-18 | 2016-09-14 | Serum Institute Of India Private Limited | A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines |
EP3131576B1 (en) | 2014-04-17 | 2021-06-30 | Medizinische Hochschule Hannover | Means and methods for producing neisseria meningitidis capsular polysaccharides of low dispersity |
BR112017017460A2 (pt) | 2015-02-19 | 2018-04-10 | Pfizer Inc. | composições de neisseria meningitidis e métodos das mesmas |
KR102225282B1 (ko) * | 2015-07-21 | 2021-03-10 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
US20170333546A1 (en) * | 2015-12-08 | 2017-11-23 | Jl Medical Corporation | Method for Producing and Vaccine Composition of Neisseria Meningitidis Serogroups A, C, Y, and W-135 Oligosaccharides Conjugated to Glycan-Free Carrier Protein |
JP2019508468A (ja) * | 2016-03-15 | 2019-03-28 | エムエスディー ウェルカム トラスト ヒルマン ラボラトリーズ プライベート リミテッドMsd Wellcome Trust Hilleman Laboratories Pvt.Ltd. | 新規の多糖体−タンパク質コンジュゲート及びそれを得る方法 |
SG11201901394XA (en) * | 2016-09-02 | 2019-03-28 | Sanofi Pasteur Inc | Neisseria meningitidis vaccine |
CA3035320A1 (en) | 2016-09-02 | 2018-03-08 | Glaxosmithkline Biologicals Sa | Vaccines for neisseria gonorrhoeae |
TW202247855A (zh) | 2016-09-13 | 2022-12-16 | 美商愛力根公司 | 非蛋白梭菌毒素組成物 |
JP6944946B2 (ja) * | 2016-10-20 | 2021-10-06 | Kmバイオロジクス株式会社 | 低分子化PRPを用いたHibコンジュゲートワクチンの製造方法 |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
AU2018215585B2 (en) | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
KR20200051005A (ko) | 2017-09-07 | 2020-05-12 | 머크 샤프 앤드 돔 코포레이션 | 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도 |
US11524076B2 (en) | 2017-09-07 | 2022-12-13 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
US20200353064A1 (en) * | 2018-01-29 | 2020-11-12 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Novel meningococcal vaccine composition and process thereof |
WO2019198096A1 (en) * | 2018-04-11 | 2019-10-17 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Tetravalent meningococcal vaccine composition and process to prepare thereof |
JOP20200214A1 (ar) | 2019-09-03 | 2021-03-03 | Serum Institute Of India Pvt Ltd | تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها |
CA3161857A1 (en) | 2019-11-22 | 2021-05-27 | Glaxosmithkline Biologicals Sa | Dosage and administration of a bacterial saccharide glycoconjugate vaccine |
CA3201450A1 (en) | 2020-11-13 | 2022-05-19 | Glaxosmithkline Biologicals Sa | Bacterial protein carriers and conjugation methods |
RU2770877C1 (ru) * | 2021-04-08 | 2022-04-22 | Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" | Способ получения антигенной конъюгированной субстанции гемофильного типа b микроба для создания вакцинных препаратов |
Family Cites Families (184)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB513069A (en) | 1937-04-24 | 1939-10-03 | Linde Air Prod Co | Improvements in method of and apparatus for the treatment of metallic bodies by oxidising gas |
GB505518A (en) † | 1938-02-03 | 1939-05-12 | Daniel Morgan Skeins | Improvements in or relating to envelopes |
US4057685A (en) * | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
US4123520A (en) * | 1977-08-01 | 1978-10-31 | Merck & Co., Inc. | Method for preparing high molecular weight meningococcal Group C vaccine |
DE2748132A1 (de) * | 1977-10-27 | 1979-05-03 | Behringwerke Ag | Stabilisator fuer polysaccharid |
US4235994A (en) * | 1978-06-26 | 1980-11-25 | Merck & Co., Inc. | High molecular weight meningococcal group C vaccine and method for preparation thereof |
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
DE3071552D1 (en) | 1979-09-21 | 1986-05-22 | Hitachi Ltd | Semiconductor switch |
DE3040825A1 (de) * | 1980-10-30 | 1982-09-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neues tridekapeptid, verfahren zu seiner herstellung und verwendung |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
HU193083B (en) * | 1984-02-22 | 1987-08-28 | Sandoz Ag | Process for preparing diazepinoindole derivatives further pharmaceutical compositions containing such compounds |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
DE3526940A1 (de) | 1985-07-27 | 1987-02-12 | Siegfried Fricker | Anker zum einbetonieren in schwere lasten |
IL78929A0 (en) | 1985-07-29 | 1986-09-30 | Abbott Lab | Microemulsion compositions for parenteral administration |
US4727136A (en) | 1985-10-01 | 1988-02-23 | Canadian Patents And Development Ltd. | Modified meningococcal group B polysaccharide for conjugate vaccine |
US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
RU2023448C1 (ru) | 1987-07-30 | 1994-11-30 | Сентро Насьональ Де Биопрепарадос | Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в |
US5180815A (en) * | 1988-04-13 | 1993-01-19 | Fuji Photo Film Co., Ltd. | Modified protein for carrying hapten |
US5115924A (en) | 1988-05-31 | 1992-05-26 | Beatrice Konig-Haug | Shelf system |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
EP0378881B1 (en) | 1989-01-17 | 1993-06-09 | ENIRICERCHE S.p.A. | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
CA2063271A1 (en) | 1989-07-14 | 1991-01-15 | Subramonia Pillai | Cytokine and hormone carriers for conjugate vaccines |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
ES2071288T3 (es) | 1989-12-14 | 1995-06-16 | Ca Nat Research Council | Vacuna mejorada de conjugado de polisacarido de meningococos. |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
ATE128628T1 (de) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff. |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
CA2059692C (en) | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
CA2059693C (en) | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae |
GB2264352A (en) | 1992-01-31 | 1993-08-25 | Richards Eng Ltd | Incineration apparatus |
ATE245446T1 (de) | 1992-02-11 | 2003-08-15 | Jackson H M Found Military Med | Dualer träger für immunogene konstrukte |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
JP3506431B2 (ja) | 1992-05-06 | 2004-03-15 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ジフテリア毒素受容体結合領域 |
NZ253065A (en) | 1992-05-23 | 1996-10-28 | Smithkline Beecham Biolog | Combination vaccines comprising hepatitis b surface antigens and other antigens wherein aluminium phosphate adjuvant is used to adsorb the hepatitis antigen |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
SG47725A1 (en) | 1992-10-27 | 1998-04-17 | American Cyanamid Co | Combination pediatric vaccine with enhanced immunogenicity of each vaccine component |
AU5951894A (en) | 1992-12-14 | 1994-07-04 | Western Atlas International, Inc. | Removable piston bore liner for hydraulically actuated seismic vibrator |
AU678613B2 (en) | 1993-09-22 | 1997-06-05 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs |
US5849301A (en) * | 1993-09-22 | 1998-12-15 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents |
DE4416166C2 (de) * | 1994-05-06 | 1997-11-20 | Immuno Ag | Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen |
US5869058A (en) * | 1994-05-25 | 1999-02-09 | Yeda Research And Development Co. Ltd. | Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines |
US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
US5917017A (en) * | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
GB9422096D0 (en) * | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine |
ATE241384T1 (de) | 1995-03-22 | 2003-06-15 | Jackson H M Found Military Med | Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden |
ES2308962T3 (es) | 1995-06-07 | 2008-12-16 | Glaxosmithkline Biologicals S.A. | Vacunas que comprenden un conjugado de antigeno polisacarido-proteina transportadora y una proteina transportadora libre. |
SI1082965T1 (sl) | 1995-06-23 | 2009-08-31 | Glaxosmithkline Biolog Sa | Sestavek cepiva, ki vsebuje antigen konjugata polisaharida, adsorbiranega na aluminijevem fosfatu |
SE9601158D0 (sv) | 1996-03-26 | 1996-03-26 | Stefan Svenson | Method of producing immunogenic products and vaccines |
EP1271490B1 (en) | 1996-10-23 | 2011-12-21 | Panasonic Corporation | Optical disk |
EP1770164B1 (en) | 1996-10-31 | 2010-09-01 | Human Genome Sciences, Inc. | Streptococcus pneumoniae antigens and vaccines |
AU1420897A (en) | 1996-12-18 | 1998-07-15 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Conjugate vaccine for (salmonella paratyphi) a |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
FR2763244B1 (fr) | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
AU4707097A (en) | 1997-09-15 | 1999-04-05 | Pasteur Merieux Serums Et Vaccins | Multivalent vaccines |
AU9399498A (en) | 1997-09-18 | 1999-04-05 | Trustees Of The University Of Pennsylvania, The | Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery |
US5965714A (en) * | 1997-10-02 | 1999-10-12 | Connaught Laboratories, Inc. | Method for the covalent attachment of polysaccharides to protein molecules |
US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
CA2264970A1 (en) | 1998-03-10 | 1999-09-10 | American Cyanamid Company | Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria |
GB9806456D0 (en) | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
GB9808932D0 (en) | 1998-04-27 | 1998-06-24 | Chiron Spa | Polyepitope carrier protein |
EP1073667A2 (en) * | 1998-04-28 | 2001-02-07 | Galenica Pharmaceuticals, Inc. | Polysaccharide-antigen conjugates |
CA2340692A1 (en) * | 1998-08-19 | 2000-03-02 | North American Vaccine, Inc. | Immunogenic .beta.-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide |
AU1626199A (en) † | 1998-12-04 | 2000-06-26 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A vi-repa conjugate vaccine for immunization against salmonella typhi |
ES2322306T3 (es) | 1998-12-21 | 2009-06-18 | Medimmune, Inc. | Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas. |
US6146902A (en) * | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
CA2363141C (en) | 1999-02-26 | 2010-04-06 | Chiron Corporation | Microemulsions with adsorbed macromolecules and microparticles |
BR0009163A (pt) * | 1999-03-19 | 2001-12-26 | Smithkline Beecham Biolog | Vacina |
JP2002541808A (ja) | 1999-04-09 | 2002-12-10 | テクラブ, インコーポレイテッド | ポリサッカリド結合体ワクチンのための組換えトキシンaタンパク質キャリア |
ES2343304T3 (es) * | 1999-06-25 | 2010-07-28 | Wyeth Holdings Corporation | Produccion de la forma lipidada de las lipoproteinas asociadas a peptidoglicano de bacterias gram-negativas. |
GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
GB9925559D0 (en) | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
ES2307553T3 (es) | 1999-12-02 | 2008-12-01 | Novartis Vaccines And Diagnostics, Inc. | Composiciones y procedimientos para estabilizar moleculas biologicas tras liofilizacion. |
FR2806304B1 (fr) * | 2000-03-17 | 2002-05-10 | Aventis Pasteur | Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
GB0108364D0 (en) | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
AU8189501A (en) * | 2000-06-29 | 2002-01-08 | Smithkline Beecham Biolog | Vaccine composition |
JP5511117B2 (ja) * | 2000-07-27 | 2014-06-04 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | 髄膜炎菌に起因する疾患に対する広域防御のためのワクチン |
GB0103170D0 (en) * | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
SG165981A1 (en) | 2000-10-27 | 2010-11-29 | Chiron Srl | Nucleic acids and proteins from streptococcus groups a & b |
PT2332581E (pt) | 2001-01-23 | 2015-10-16 | Sanofi Pasteur Inc | Vacina meningocócica tri- ou tetravalente de conjugados de polissacárido e crm-197 |
GB0107661D0 (en) * | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
GB0107658D0 (en) * | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
US6615062B2 (en) | 2001-05-31 | 2003-09-02 | Infraredx, Inc. | Referencing optical catheters |
GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
AR045702A1 (es) * | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
CU23031A1 (es) | 2002-01-24 | 2005-02-23 | Ct Ingenieria Genetica Biotech | Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes |
CN100593544C (zh) | 2002-03-15 | 2010-03-10 | 惠氏控股有限公司 | 酶活性减少的非典型流感嗜血杆菌的p4蛋白突变体 |
DE60325565D1 (de) * | 2002-03-26 | 2009-02-12 | Novartis Vaccines & Diagnostic | Modifizierte saccharide mit verbesserter stabilität in wasser |
GB0210128D0 (en) * | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
CA2485999C (en) | 2002-05-14 | 2015-02-17 | Chiron Srl | Mucosal combination vaccines for bacterial meningitis |
GB0302218D0 (en) * | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
MXPA04011249A (es) * | 2002-05-14 | 2005-06-06 | Chiron Srl | Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos. |
GB0211118D0 (en) * | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
AU2003257003A1 (en) * | 2002-07-30 | 2004-02-16 | Baxter Healthcare S.A. | Chimeric multivalent polysaccharide conjugate vaccines |
GB0220199D0 (en) * | 2002-08-30 | 2002-10-09 | Univ Utrecht | Mutant protein and refolding method |
CA2493124C (en) | 2002-08-02 | 2014-04-29 | Glaxosmithkline Biologicals S.A. | Vaccine |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
ATE492288T1 (de) | 2002-10-11 | 2011-01-15 | Novartis Vaccines & Diagnostic | Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien |
CN1401328A (zh) | 2002-10-18 | 2003-03-12 | 北京绿竹生物技术有限责任公司 | 流行性脑脊髓膜炎多糖-蛋白结合疫苗 |
BR0315767A (pt) * | 2002-11-01 | 2005-09-06 | Glaxosmithkline Biolog Sa | Composição imunogência, método para fabricar uma vacina, kit, vacina, recipiente com uma superfìcie interna repelente à água, e, método para preservar uma composição que compreende ipv e um agente estabilizador |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
CN1168501C (zh) | 2002-12-27 | 2004-09-29 | 北京绿竹生物技术有限责任公司 | 一种多糖-蛋白结合疫苗 |
JP4827726B2 (ja) * | 2003-01-30 | 2011-11-30 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 複数の髄膜炎菌血清群に対する注射可能ワクチン |
AU2004219910B2 (en) * | 2003-03-13 | 2010-06-17 | Glaxosmithkline Biologicals S.A. | Purification process for bacterial cytolysin |
CA2519511A1 (en) | 2003-03-17 | 2004-09-30 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
AU2004240558A1 (en) | 2003-05-07 | 2004-12-02 | Aventis Pasteur, Inc. | Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines |
ES2596553T3 (es) | 2003-06-02 | 2017-01-10 | Glaxosmithkline Biologicals Sa | Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido |
GB0313916D0 (en) | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
EP2364725A3 (en) * | 2003-06-23 | 2012-05-09 | Sanofi Pasteur Inc. | Immunization method against neisseria meningitidis serogroups a and c |
KR101034055B1 (ko) | 2003-07-18 | 2011-05-12 | 엘지이노텍 주식회사 | 발광 다이오드 및 그 제조방법 |
EP1651261B1 (en) * | 2003-08-06 | 2014-10-08 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Polysaccharide-protein conjugate vaccines |
US8048432B2 (en) * | 2003-08-06 | 2011-11-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
WO2005022583A2 (en) * | 2003-08-21 | 2005-03-10 | Applera Corporation | Reduction of matrix interference for maldi mass spectrometry analysis |
WO2005032584A2 (en) * | 2003-10-02 | 2005-04-14 | Glaxosmithkline Biologicals S.A. | Pertussis antigens and use thereof in vaccination |
CN103357002A (zh) * | 2003-10-02 | 2013-10-23 | 诺华疫苗和诊断有限公司 | 多种脑膜炎球菌血清群的液体疫苗 |
US7628995B2 (en) | 2003-12-23 | 2009-12-08 | Glaxosmithkline Biologicals S.A. | Outer membrane vesicles and uses thereof |
GB0405787D0 (en) | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
DK1742659T3 (da) * | 2004-04-05 | 2013-06-03 | Zoetis P Llc | Mikrofluidiserede olie-i-vand-emulsioner og vaccinesammensætninger |
RU2379052C2 (ru) | 2004-04-30 | 2010-01-20 | Чирон С.Р.Л. | Вакцинация менингококковыми конъюгатами |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
GB0409745D0 (en) * | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
GB0413868D0 (en) * | 2004-06-21 | 2004-07-21 | Chiron Srl | Dimensional anlaysis of saccharide conjugates |
EP1793849A2 (en) * | 2004-09-22 | 2007-06-13 | GlaxoSmithKline Biologicals SA | Immunogenic composition for use in vaccination against staphylococcei |
US20060121055A1 (en) | 2004-12-06 | 2006-06-08 | Becton, Dickinson And Company, Inc. | Compositions with enhanced immunogenicity |
GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
GB0502095D0 (en) * | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
EP1858920B1 (en) | 2005-02-18 | 2016-02-03 | GlaxoSmithKline Biologicals SA | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
GB0505518D0 (en) | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
KR101730748B1 (ko) | 2005-04-08 | 2017-04-26 | 와이어쓰 엘엘씨 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
ES2533248T3 (es) * | 2005-05-06 | 2015-04-08 | Novartis Ag | Inmunógenos para vacunas contra Meningitidis A |
US8431136B2 (en) * | 2005-06-27 | 2013-04-30 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
CN1709505B (zh) | 2005-07-13 | 2010-06-16 | 北京绿竹生物制药有限公司 | 多价细菌荚膜多糖-蛋白质结合物联合疫苗 |
RU2457858C2 (ru) | 2005-09-01 | 2012-08-10 | Новартис Вэксинес Энд Дайэгностикс Гмбх Унд Ко Кг | Множественная вакцинация, включающая менингококки серогруппы с |
CA2621578C (en) * | 2005-09-05 | 2014-07-22 | Glaxosmithkline Biologicals S.A. | Serum bactericidal assay for n. meningitidis specific antisera |
GB0522765D0 (en) * | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
JO2813B1 (en) * | 2005-12-22 | 2014-09-15 | جلاكسو سميث كلاين بايولوجيكالز اس.ايه | A vaccine with multiple pneumococcal saccharides |
GB0607088D0 (en) * | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
CA2633789A1 (en) | 2005-12-23 | 2007-06-28 | Glaxosmithkline Biologicals Sa | Conjugate vaccines |
CA2644724C (en) * | 2006-03-17 | 2016-05-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for preparing complex multivalent immunogenic conjugates |
AR060188A1 (es) * | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Procedimiento de conjugacion |
MX337528B (es) * | 2006-03-30 | 2016-03-09 | Glaxosmithkline Biolog Sa | Composición inmunogénica que comprende un sacárido capsular estafilocócico o-acetilado y una proteína estafilocócica. |
CA2656474A1 (en) * | 2006-06-29 | 2008-01-03 | Novartis Ag | Polypeptides from neisseria meningitidis |
US7491517B2 (en) * | 2006-07-19 | 2009-02-17 | Jeeri R Reddy | Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135 |
AU2007275693A1 (en) | 2006-07-21 | 2008-01-24 | Albert Einstein College Of Medicine | Human endogenous retrovirus polypeptide compositions and methods of use thereof |
EP2066344B2 (en) * | 2006-09-07 | 2016-06-29 | GlaxoSmithKline Biologicals S.A. | Inactivated Poliovirus combination vaccine |
GB0700136D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Process for manufacturing vaccines |
GB0700135D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Vaccine |
JP4858611B2 (ja) * | 2007-03-14 | 2012-01-18 | コニカミノルタビジネステクノロジーズ株式会社 | 情報埋め込み方法、そのプログラムおよび情報埋め込み装置 |
EA201490303A1 (ru) * | 2007-05-02 | 2014-05-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина |
EP2152302B1 (en) | 2007-06-04 | 2015-10-07 | GlaxoSmithKline Biologicals SA | Formulation of meningitis vaccines |
PT2167121E (pt) * | 2007-06-26 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vacina compreendendo conjugados de polissacáridos capsulares de streptococcus pneumoniae |
GB0714963D0 (en) * | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
JP5769624B2 (ja) * | 2008-08-28 | 2015-08-26 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
GB0816447D0 (en) * | 2008-09-08 | 2008-10-15 | Glaxosmithkline Biolog Sa | Vaccine |
US8259461B2 (en) * | 2008-11-25 | 2012-09-04 | Micron Technology, Inc. | Apparatus for bypassing faulty connections |
CA2779798C (en) * | 2009-09-30 | 2019-03-19 | Novartis Ag | Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides |
TW201136603A (en) * | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
GB201003922D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
CN103124737A (zh) * | 2010-03-11 | 2013-05-29 | 葛兰素史密丝克莱恩生物有限公司 | 针对革兰氏阴性菌例如奈瑟菌属感染或疾病的免疫原性组合物或疫苗 |
CN102781322B (zh) * | 2010-06-11 | 2015-02-25 | 松下电器产业株式会社 | 语音听取的评价系统、及方法 |
CN104080479B (zh) * | 2011-11-07 | 2019-11-05 | 葛兰素史密丝克莱恩生物有限公司 | 包括spr0096和spr2021抗原的运载体分子 |
GB2495341B (en) * | 2011-11-11 | 2013-09-18 | Novartis Ag | Fermentation methods and their products |
CA2863178C (en) * | 2012-01-30 | 2021-04-06 | Serum Institute Of India Ltd. | Immunogenic composition |
MX2014014067A (es) * | 2012-05-22 | 2015-02-04 | Novartis Ag | Conjugado de serogrupo x de meningococo. |
WO2014001328A1 (en) | 2012-06-25 | 2014-01-03 | Nadiro A/S | A lifeboat deployment unit |
CN112807422A (zh) * | 2012-12-05 | 2021-05-18 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
GB201310008D0 (en) * | 2013-06-05 | 2013-07-17 | Glaxosmithkline Biolog Sa | Immunogenic composition for use in therapy |
AR101455A1 (es) * | 2014-08-05 | 2016-12-21 | Glaxosmithkline Biologicals Sa | Molécula portadora |
TWI715617B (zh) * | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
GB201518684D0 (en) * | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
SG11201901394XA (en) * | 2016-09-02 | 2019-03-28 | Sanofi Pasteur Inc | Neisseria meningitidis vaccine |
US11951165B2 (en) * | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
AU2018215585B2 (en) * | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
CA3070039A1 (en) * | 2017-07-18 | 2019-01-24 | Serum Institute Of India Pvt Ltd. | An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof |
-
2006
- 2006-06-23 US US11/917,569 patent/US8431136B2/en active Active
- 2006-06-23 WO PCT/EP2006/006220 patent/WO2007000327A1/en active Application Filing
- 2006-06-23 BR BRPI0612655-3A patent/BRPI0612655B1/pt active IP Right Grant
- 2006-06-23 KR KR1020077030683A patent/KR101359953B1/ko active IP Right Grant
- 2006-06-23 PT PT06754599T patent/PT1896063E/pt unknown
- 2006-06-23 US US11/917,726 patent/US8398983B2/en active Active
- 2006-06-23 BR BRPI0612654A patent/BRPI0612654B8/pt active IP Right Grant
- 2006-06-23 AR ARP060102725A patent/AR053935A1/es not_active Application Discontinuation
- 2006-06-23 SI SI200631109T patent/SI1896065T2/sl unknown
- 2006-06-23 JP JP2008517442A patent/JP5731737B2/ja active Active
- 2006-06-23 AR ARP060102724A patent/AR056397A1/es not_active Application Discontinuation
- 2006-06-23 KR KR1020077031058A patent/KR101351873B1/ko not_active IP Right Cessation
- 2006-06-23 DK DK10177832T patent/DK2283857T3/da active
- 2006-06-23 AU AU2006263964A patent/AU2006263964B2/en active Active
- 2006-06-23 MX MX2007016402A patent/MX2007016402A/es active IP Right Grant
- 2006-06-23 JP JP2008517437A patent/JP5037503B2/ja active Active
- 2006-06-23 PE PE2006000718A patent/PE20070123A1/es not_active Application Discontinuation
- 2006-06-23 AU AU2006263944A patent/AU2006263944B2/en active Active
- 2006-06-23 PL PL06754596T patent/PL1896062T3/pl unknown
- 2006-06-23 SI SI200632415T patent/SI3009146T1/sl unknown
- 2006-06-23 EP EP06754582.2A patent/EP1896061B1/en active Active
- 2006-06-23 WO PCT/EP2006/006210 patent/WO2007000322A1/en not_active Application Discontinuation
- 2006-06-23 WO PCT/EP2006/006269 patent/WO2007000342A2/en active Application Filing
- 2006-06-23 AR ARP060102723A patent/AR056396A1/es not_active Application Discontinuation
- 2006-06-23 PE PE2010000450A patent/PE20110072A1/es not_active Application Discontinuation
- 2006-06-23 SI SI200631247T patent/SI1896063T1/sl unknown
- 2006-06-23 DE DE602006013313T patent/DE602006013313D1/de active Active
- 2006-06-23 EP EP10158046.2A patent/EP2201961B1/en active Active
- 2006-06-23 US US11/917,702 patent/US9486515B2/en active Active
- 2006-06-23 AP AP2007004274A patent/AP2436A/xx active
- 2006-06-23 AU AU2006263963A patent/AU2006263963B2/en active Active
- 2006-06-23 ES ES14198052T patent/ES2747025T3/es active Active
- 2006-06-23 WO PCT/EP2006/006188 patent/WO2007000314A2/en active Application Filing
- 2006-06-23 AT AT06754611T patent/ATE516816T1/de active
- 2006-06-23 EA EA200702577A patent/EA013374B1/ru not_active IP Right Cessation
- 2006-06-23 AU AU2006263965A patent/AU2006263965B2/en active Active
- 2006-06-23 ES ES06762248T patent/ES2901378T3/es active Active
- 2006-06-23 JP JP2008517440A patent/JP2008543907A/ja active Pending
- 2006-06-23 CA CA2611960A patent/CA2611960C/en active Active
- 2006-06-23 BR BRPI0612670A patent/BRPI0612670B8/pt active IP Right Grant
- 2006-06-23 NZ NZ564370A patent/NZ564370A/en unknown
- 2006-06-23 EP EP06762248.0A patent/EP1896066B8/en active Active
- 2006-06-23 PE PE2006000720A patent/PE20070499A1/es active IP Right Grant
- 2006-06-23 PL PL14198052T patent/PL2878307T3/pl unknown
- 2006-06-23 UA UAA200714086A patent/UA95238C2/uk unknown
- 2006-06-23 DK DK06754611.9T patent/DK1896065T4/da active
- 2006-06-23 KR KR1020087002217A patent/KR101351870B1/ko active IP Right Grant
- 2006-06-23 CA CA2612963A patent/CA2612963C/en active Active
- 2006-06-23 PT PT101778322T patent/PT2283857T/pt unknown
- 2006-06-23 DK DK06754582.2T patent/DK1896061T3/da active
- 2006-06-23 MX MX2007016405A patent/MX2007016405A/es active IP Right Grant
- 2006-06-23 DK DK14198052.4T patent/DK2878307T3/da active
- 2006-06-23 KR KR1020137028209A patent/KR20130122810A/ko not_active Application Discontinuation
- 2006-06-23 PL PL06754611T patent/PL1896065T5/pl unknown
- 2006-06-23 PT PT101798205T patent/PT2351578T/pt unknown
- 2006-06-23 MX MX2007016236A patent/MX2007016236A/es active IP Right Grant
- 2006-06-23 PE PE2014001334A patent/PE20142165A1/es active IP Right Grant
- 2006-06-23 HU HUE14198052A patent/HUE046905T2/hu unknown
- 2006-06-23 DK DK06754596.2T patent/DK1896062T3/da active
- 2006-06-23 AT AT06754596T patent/ATE462444T1/de active
- 2006-06-23 KR KR1020137018446A patent/KR101532068B1/ko active IP Right Grant
- 2006-06-23 EA EA200702576A patent/EA012506B1/ru not_active IP Right Cessation
- 2006-06-23 EP EP10177832.2A patent/EP2283857B1/en active Active
- 2006-06-23 KR KR1020087002312A patent/KR101408113B1/ko active IP Right Grant
- 2006-06-23 US US11/917,580 patent/US8329184B2/en active Active
- 2006-06-23 HU HUE10177832A patent/HUE047211T2/hu unknown
- 2006-06-23 SI SI200632159A patent/SI2351578T1/sl unknown
- 2006-06-23 NO NO20076343A patent/NO345422B1/no active Protection Beyond IP Right Term
- 2006-06-23 PE PE2010000444A patent/PE20110096A1/es active IP Right Grant
- 2006-06-23 DK DK06754599.6T patent/DK1896063T3/da active
- 2006-06-23 NZ NZ564606A patent/NZ564606A/en unknown
- 2006-06-23 UA UAA200714084A patent/UA95237C2/uk unknown
- 2006-06-23 ES ES06754596T patent/ES2340711T3/es active Active
- 2006-06-23 WO PCT/EP2006/006268 patent/WO2007000341A2/en active Application Filing
- 2006-06-23 EP EP06754596A patent/EP1896062B1/en not_active Revoked
- 2006-06-23 ES ES15189397T patent/ES2898451T3/es active Active
- 2006-06-23 EP EP15189397.1A patent/EP3009146B1/en active Active
- 2006-06-23 AT AT06754599T patent/ATE536884T1/de active
- 2006-06-23 EP EP06754599.6A patent/EP1896063B2/en active Active
- 2006-06-23 SI SI200632352T patent/SI2878307T1/sl unknown
- 2006-06-23 KR KR1020077030681A patent/KR101321056B1/ko active IP Right Grant
- 2006-06-23 CN CN2011101438611A patent/CN102218138A/zh active Pending
- 2006-06-23 PT PT151893971T patent/PT3009146T/pt unknown
- 2006-06-23 EA EA200702575A patent/EA012528B1/ru not_active IP Right Cessation
- 2006-06-23 JP JP2008517436A patent/JP5280199B2/ja active Active
- 2006-06-23 LT LTEP10179820.5T patent/LT2351578T/lt unknown
- 2006-06-23 EP EP06754610A patent/EP1896064A2/en not_active Ceased
- 2006-06-23 PL PL06754599T patent/PL1896063T3/pl unknown
- 2006-06-23 ES ES10177832T patent/ES2750243T3/es active Active
- 2006-06-23 MX MX2007016237A patent/MX2007016237A/es active IP Right Grant
- 2006-06-23 MX MX2007016403A patent/MX2007016403A/es active IP Right Grant
- 2006-06-23 PL PL15189397T patent/PL3009146T3/pl unknown
- 2006-06-23 PT PT141980524T patent/PT2878307T/pt unknown
- 2006-06-23 PT PT06754596T patent/PT1896062E/pt unknown
- 2006-06-23 ES ES10158046.2T patent/ES2662651T3/es active Active
- 2006-06-23 SI SI200630681T patent/SI1896062T1/sl unknown
- 2006-06-23 PE PE2006000719A patent/PE20070163A1/es active IP Right Grant
- 2006-06-23 SI SI200632346T patent/SI1896061T1/sl unknown
- 2006-06-23 EP EP06754611.9A patent/EP1896065B2/en active Active
- 2006-06-23 PT PT06754611T patent/PT1896065E/pt unknown
- 2006-06-23 ES ES06754599.6T patent/ES2377075T5/es active Active
- 2006-06-23 PL PL06754582T patent/PL1896061T3/pl unknown
- 2006-06-23 DK DK10179820.5T patent/DK2351578T3/en active
- 2006-06-23 HU HUE06754582A patent/HUE045482T2/hu unknown
- 2006-06-23 SI SI200632356T patent/SI2283857T1/sl unknown
- 2006-06-23 PL PL10177832T patent/PL2283857T3/pl unknown
- 2006-06-23 CN CN201210028358.6A patent/CN102526723B/zh active Active
- 2006-06-23 CA CA2612980A patent/CA2612980C/en active Active
- 2006-06-23 CA CA2611964A patent/CA2611964C/en active Active
- 2006-06-23 CA CA2612957A patent/CA2612957C/en active Active
- 2006-06-23 AU AU2006263936A patent/AU2006263936B2/en active Active
- 2006-06-23 NZ NZ564607A patent/NZ564607A/en unknown
- 2006-06-23 US US11/917,709 patent/US9931397B2/en active Active
- 2006-06-23 WO PCT/EP2006/006270 patent/WO2007000343A2/en active Application Filing
- 2006-06-23 BR BRPI0612656-1A patent/BRPI0612656B1/pt active IP Right Grant
- 2006-06-23 ES ES06754582T patent/ES2741529T3/es active Active
- 2006-06-23 ES ES10179820.5T patent/ES2621780T3/es active Active
- 2006-06-23 NZ NZ590204A patent/NZ590204A/en unknown
- 2006-06-23 HU HUE15189397A patent/HUE056842T2/hu unknown
- 2006-06-23 CN CN201310023297.9A patent/CN103083657B/zh active Active
- 2006-06-23 US US11/917,610 patent/US9789179B2/en active Active
- 2006-06-23 PL PL10179820T patent/PL2351578T3/pl unknown
- 2006-06-23 EP EP14198052.4A patent/EP2878307B1/en active Active
- 2006-06-23 HU HUE10179820A patent/HUE031380T2/en unknown
- 2006-06-23 NZ NZ564605A patent/NZ564605A/en unknown
- 2006-06-23 EP EP10179820.5A patent/EP2351578B1/en active Active
- 2006-06-23 JP JP2008517441A patent/JP5297800B2/ja active Active
- 2006-06-23 PT PT06754582T patent/PT1896061T/pt unknown
- 2006-06-23 NZ NZ564371A patent/NZ564371A/en not_active IP Right Cessation
- 2006-06-23 EA EA200702574A patent/EA012214B1/ru not_active IP Right Cessation
- 2006-06-23 BR BRPI0612669A patent/BRPI0612669B8/pt active IP Right Grant
- 2006-06-26 TW TW102148542A patent/TWI537001B/zh active
- 2006-06-26 TW TW095122979A patent/TWI407970B/zh active
- 2006-06-26 TW TW095122993A patent/TWI477283B/zh active
- 2006-06-26 MY MYPI20063025A patent/MY147490A/en unknown
- 2006-06-26 MY MYPI20063023A patent/MY148110A/en unknown
- 2006-06-26 TW TW095122969A patent/TWI422386B/zh active
- 2006-06-26 MY MYPI20063024A patent/MY147783A/en unknown
- 2006-06-26 TW TW102118476A patent/TW201336507A/zh unknown
-
2007
- 2007-12-06 IL IL187924A patent/IL187924A/en active IP Right Grant
- 2007-12-07 NO NO20076302A patent/NO344452B1/no unknown
- 2007-12-11 NO NO20076350A patent/NO342815B1/no unknown
- 2007-12-11 IL IL188046A patent/IL188046A/en active IP Right Grant
- 2007-12-11 IL IL188045A patent/IL188045A0/en active IP Right Grant
- 2007-12-12 IL IL188072A patent/IL188072A/en active IP Right Grant
- 2007-12-12 NO NO20076363A patent/NO345305B1/no unknown
- 2007-12-26 MA MA30511A patent/MA29602B1/fr unknown
- 2007-12-26 MA MA30512A patent/MA29603B1/fr unknown
- 2007-12-27 MA MA30521A patent/MA29569B1/fr unknown
- 2007-12-27 MA MA30522A patent/MA29993B1/fr unknown
-
2008
- 2008-04-10 HK HK08104083.2A patent/HK1114011A1/xx active IP Right Maintenance
- 2008-06-12 HK HK15105322.1A patent/HK1206587A1/xx unknown
- 2008-06-17 HK HK08106654.6A patent/HK1116414A1/xx not_active IP Right Cessation
- 2008-06-17 HK HK08106653.7A patent/HK1116413A1/xx not_active IP Right Cessation
-
2010
- 2010-04-14 HR HR20100211T patent/HRP20100211T1/hr unknown
- 2010-04-30 CY CY20101100387T patent/CY1109996T1/el unknown
- 2010-07-21 AU AU2010203115A patent/AU2010203115C1/en active Active
- 2010-08-18 AU AU2010212417A patent/AU2010212417A1/en not_active Abandoned
-
2011
- 2011-06-22 IL IL213718A patent/IL213718A/en active IP Right Grant
- 2011-06-28 IL IL213795A patent/IL213795A/en active IP Right Grant
- 2011-07-29 HR HRP20110567TT patent/HRP20110567T4/hr unknown
- 2011-08-15 IL IL214657A patent/IL214657A0/en unknown
- 2011-09-15 CY CY20111100883T patent/CY1111827T1/el unknown
-
2012
- 2012-02-01 HR HR20120102T patent/HRP20120102T1/hr unknown
- 2012-02-21 CY CY20121100175T patent/CY1112698T1/el unknown
- 2012-04-27 US US13/457,891 patent/US8846049B2/en active Active
- 2012-10-11 IL IL222346A patent/IL222346A/en active IP Right Grant
- 2012-10-16 CY CY2012027C patent/CY2012027I1/el unknown
- 2012-10-18 BE BE2012C042C patent/BE2012C042I2/fr unknown
- 2012-10-19 HU HUS1200023C patent/HUS1200023I1/hu unknown
- 2012-10-19 LU LU92085C patent/LU92085I2/fr unknown
- 2012-10-19 NL NL300549C patent/NL300549I2/nl unknown
- 2012-11-01 JP JP2012241817A patent/JP5769688B2/ja active Active
-
2013
- 2013-02-27 US US13/778,633 patent/US8883163B2/en active Active
- 2013-03-13 JP JP2013050333A patent/JP5718960B2/ja active Active
- 2013-05-14 JP JP2013102249A patent/JP2013209395A/ja active Pending
-
2014
- 2014-10-28 US US14/525,883 patent/US9358279B2/en active Active
-
2015
- 2015-04-28 JP JP2015091394A patent/JP5965512B2/ja active Active
-
2016
- 2016-09-14 US US15/265,597 patent/US10245317B2/en active Active
-
2017
- 2017-02-21 CY CY20171100234T patent/CY1118646T1/el unknown
- 2017-03-20 HR HRP20170457TT patent/HRP20170457T1/hr unknown
- 2017-08-30 US US15/691,440 patent/US10166287B2/en active Active
-
2018
- 2018-11-02 US US16/179,476 patent/US11241495B2/en active Active
-
2019
- 2019-02-05 US US16/268,287 patent/US20200000911A1/en not_active Abandoned
-
2022
- 2022-01-13 HU HUS2200002C patent/HUS2200002I1/hu unknown
- 2022-02-21 FR FR22C1008C patent/FR22C1008I2/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR056396A1 (es) | Composicion inmunogenica | |
CR10348A (es) | Composicion inmunogenica | |
PE20110065A1 (es) | Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de staphylococcus aureus serotipos 5 y 8 | |
CL2016000566A1 (es) | Método para para preparar una composición inmunogénica multivalente que comprende 13 conjugados de un serotipo diferente de streptococcus pneumoniae, donde cada uno de los conjugados contiene un polisacárido capsular diferente conjugado a la proteína portadora crm197. div. sol. madre n° 200600802 e hija cl 201702206. | |
AR058592A1 (es) | Vacuna | |
BRPI0407101A (pt) | Vacinas meningocócicas mucosais | |
EA200801368A1 (ru) | Конъюгатные вакцины | |
RU2007102016A (ru) | Пространственный анализ конъюгатов сахаридов с помощью gpc и sec-mals | |
CL2007003780A1 (es) | Metodo para preparar conjugados que comprenden polisacaridos de strptococcus pneumoniae y una proteina carrier | |
BRPI0721136B8 (pt) | método para produzir um conjugado imunogênico que compreende polissacarídeo de streptococcus pneumoniae sorotipo 1 encadeado de modo covalente a uma proteína de veículo | |
BR0206672A (pt) | Vacina conjugada de proteìna de polissacarìdeo meningocócico multivalente | |
PT1284998E (pt) | Eptideos imunogenicos sinteticos mas nao-amiloidogenicos homologos a beta-amiloides, destinados a induzir uma reaccao imunitaria contra os beta-amiloides e os depositos amiloides | |
AR084158A1 (es) | Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas | |
ATE419278T1 (de) | Modifizierte saccharide mit verbesserter stabilität in wasser | |
CR10101A (es) | Nueva composición | |
AR066376A1 (es) | Vacuna | |
AR047651A1 (es) | Composicion alimenticia con fibras | |
BRPI0516770A (pt) | vacina e conjugados de proteìna - derivados de polissacarìdeo de meningocócico multivalente | |
BRPI0515125A (pt) | conjugados de polissacarìdeo derivatizado-proteìna multivalentes, meningocócicos e vacina | |
BRPI0516372A (pt) | conjugados de polissacarìdeo-proteìna derivatizados meningocócicos multivalentes e vacina | |
CO2023016246A2 (es) | Composiciones inmunógenas que comprenden antígenos de sacárido capsular conjugados y sus usos | |
BRPI0411815A (pt) | vacinas contra neisseria meningitidis do tipo y e suas combinações meningocócicas | |
UA95075C2 (uk) | Імуногенна композиція | |
WO2022249107A3 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
PE20080774A1 (es) | Composicion inmunogenica que comprende pnag de estafilococos conjugada con una proteina portadora y polisacarido u oligosacarido capsular de s. aureus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |